DonCorleone77 Posted - 6 days ago

$TYRA Tyra Biosciences appoints Doug Warner as Chief Medical Officer Tyra Biosciences announced the appointment of Doug Warner, as Chief Medical Officer. Warner will be responsible for overseeing TYRA's clinical portfolio and will serve as a key member of its executive management team. Warner held roles of increasing responsibility over 18 years at Amgen where he oversaw clinical development for programs across oncology and bone diseases. This included being an Executive Director and Group Product Area Lead, where Dr. Warner led a team responsible for the development of a portfolio of medicines ranging from those in Phase 1 to those with approved indications, including Vectibix, XGEVA, and Prolia. Most recently, Warner was Chief Medical Officer for eFFECTOR Therapeutics where he was responsible for overseeing eFFECTOR's clinical pipeline, including its KICKSTART Phase 2b trial of tomivosertib in non-small cell lung cancer, and its Phase 1/2 study of zotatifin in solid tumors. Dr. Warner is co-author of numerous peer-reviewed articles including those in The Lancet, The Lancet Oncology, and The Journal of Clinical Oncology.

insidemoney Posted - 08/27/24

$TYRA Tyra Biosciences, Inc. 14-Day RSI: 69.4 % from 52-Week Low: +114.8% % from 52-Week High: -8.0% Open Interest: 1,560 % Change: 0% Put/Call Ratio: 0.02 % Change: 0.0%

Stock_Titan Posted - 08/27/24

$TYRA An Inquiry Has Been Opened Into Tyra Biosciences Inc’s Possible Securities Related Impropriety And Impacted Stakeholders Should Join https://www.stocktitan.net/news/TYRA/an-inquiry-has-been-opened-into-tyra-biosciences-inc-s-possible-jzzcl4f8pnm5.html

insidemoney Posted - 08/23/24

Options Spikes (Aug 22) $TYRA Tyra Biosciences % Change -4.80% Trade Count 5 Total Notional 152.5 K 90 Day Average 4.8 K Calls 151.8 K Puts 680 $SUPN Supernus Pharmaceuticals % Change -0.70%Trade Count 33 Total Notional 333.5 K 90 Day Average 12.5 K Calls 304.2 K Puts 29.3 K

Stock_Titan Posted - 1 month ago

$TYRA Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights https://www.stocktitan.net/news/TYRA/tyra-biosciences-reports-second-quarter-2024-financial-results-and-d87yo9q7dq15.html

NVDAMillionaire Posted - 07/31/24

$TYRA Tyra Biosciences, Inc. (NASDAQ:TYRA): Developing Next-Generation Precision Medicines for Unmet Needs http://beyondspx.com/2024/07/30/tyra-biosciences-inc-nasdaqtyra-developing-next-generation-precision-medicines-for-unmet-needs/

DonCorleone77 Posted - 2 months ago

$TYRA Tyra Biosciences 'rapidly becoming' top second half pick at Opco Oppenheimer reiterates an Outperform rating on Tyra Biosciences with a $28 price target, saying the company is "rapidly becoming" a top pick for the second half of 2024. "The fact that Tyra shares have been resilient despite the long wait for Phase 1 data tells us the story is resonating with investors," the analyst tells investors in a research note. Urothelial cancer and achondroplasia are each $2B-plus markets and TYRA-300 is "head-and-shoulders better than competitors," the firm contends. It believes Vosoritide's recent data showed that increasing height velocity can be done safety removes a common misperception to Tyra's approach.

DonCorleone77 Posted - 2 months ago

$TYRA Tyra Biosciences reports preclinical proof-of-concept results with TYRA-300 Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300, an investigational oral FGFR3 selective inhibitor, in hypochondroplasia, or HCH. The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference, held June 28-30,in Baltimore. HCH is a skeletal dysplasia closely related to achondroplasia, or ACH, the most common form of dwarfism. HCH is most commonly caused by the N540K mutation in the FGFR3 gene. There are currently no approved therapeutic options for HCH. The design of TYRA-300 may inhibit the alteration driving FGFR3-related skeletal dysplasias including ACH, HCH and others. In an Fgfr3Asn534Lys/+ preclinical model, TYRA-300 was evaluated in FGFR3 wild-type and mutant animals to evaluate its potential effect on long bone length and skull size compared to vehicle-treated mice. TYRA-300 was administered daily at 1.8 mg/kg/day for 21 days starting at Day 3. TYRA-300 increased the length of the appendicular skeleton in the FGFR3 mutated mice: femur by 3.70% compared to the vehicle; tibia by 3.75% compared to the vehicle; humerus by 3.22% compared to the vehicle; and ulna by 5.03% compared to the vehicle. TYRA-300 also increased the size of the foramen magnum by 5.88% in mice. TYRA-300 demonstrated binding against the FGFR3 N540K altered protein and isoform selectivity for FGFR3 over other isoforms, as previously reported.

Stock_Titan Posted - 2 months ago

$TYRA Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) https://www.stocktitan.net/news/TYRA/tyra-biosciences-announces-preclinical-proof-of-concept-results-with-o7ovg79q5b4b.html

Stocksrunner Posted - 3 months ago

$TYRA has been on a roll, with a recent 11.5% gain. With analysts forecasting further upside, it’s a stock to keep an eye on for potential breakout opportunities.

DonCorleone77 Posted - 4 months ago

$TYRA Tyra Biosciences price target raised to $28 from $25 at Oppenheimer Oppenheimer raised the firm's price target on Tyra Biosciences to $28 from $25 and keeps an Outperform rating on the shares following the company's Q1 earnings results. The firm noted that it has recently noticed an uptick in investor interest in the story, which it feels "isn't surprising as we approach initial data from SURF301 later this year."

Thestocktraderhubzee Posted - 4 months ago

$TYRA HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $23 Price Target

DonCorleone77 Posted - 4 months ago

$TYRA Tyra Biosciences reports Q1 EPS (35c), consensus (45c) "During the first quarter of 2024, we focused on execution across our pipeline including delivering on our near-term milestones for TYRA-300 in both achondroplasia and oncology," said Todd Harris, CEO of TYRA. "In oncology, the TYRA-300 clinical profile continues to mature in SURF301, and our clinical team is focused on Part B dose expansion to evaluate multiple dosing regimens of TYRA-300. We believe this work will support future Phase 2 studies in NMIBC and metastatic urothelial carcinoma, where we see tremendous opportunity for an oral FGFR3-selective inhibitor. In achondroplasia, we remain on track to submit our IND in the second half of 2024 to support our planned Phase 2 study."

Stock_Titan Posted - 4 months ago

$TYRA Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights https://www.stocktitan.net/news/TYRA/tyra-biosciences-reports-first-quarter-2024-financial-results-and-0urr5hljmef3.html

Doozio Posted - 4 months ago

$TYRA wen 🧠⏰ if no faatch 💣?

DailyStocksPicks Posted - 03/24/24

Acelyrin ($SLRN): Acelyrin’s stock is perceived as oversold due to the divergence between its clinical advancements, institutional support, and analysts' optimistic forecasts versus its recent stock performance. Despite facing downward pressure, the company’s engagement in critical clinical trials and backing from notable institutional investors suggest an underappreciation of its value and potential, especially when considering its innovative pipeline in addressing unmet medical needs. $TYRA, $ZYME, $PHVS, $WVE For More Details: https://youtu.be/yeL_bMBSsNQ

erevnon Posted - 03/21/24

Wedbush reiterates Tyra Biosciences $TYRA at Outperform and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

fda_tracker Posted - 03/20/24

$TYRA New PDUFA Date 2024-04-23 Tyra Biosciences, Inc. Link:https://www.sec.gov/Archives/edgar/data/0001863127/000095017024033461/tyra-20231231.htm Calendar:http://www.fdatracker.com/fda-calendar/

erevnon Posted - 03/20/24

HC Wainwright & Co. reiterates Tyra Biosciences $TYRA at Buy and raises the price target from $19 to https://marketsblock.com/stock-upgrades-and-downgrades/

DonCorleone77 Posted - 03/19/24

$TYRA Tyra Biosciences files to sell 15.37M shares of common stock for holders

DonCorleone77 Posted - 03/19/24

$TYRA Tyra Biosciences reports Q4 EPS (53c), consensus (48c) As of December 31, 2023, TYRA had cash, cash equivalents, and marketable securities of $203.5M. "2023 was an outstanding year for TYRA and we are pleased to have positive momentum at the start of 2024," said Todd Harris, CEO of TYRA. "We have strong conviction in our pipeline and believe our lead program TYRA-300 has the potential to become a best-in-class agent for multiple high-value indications. TYRA-300 remains our top priority and we are focused on submitting our Phase 2 IND for achondroplasia, while optimizing dose in SURF301 in preparation for Phase 2 studies in NMIBC and metastatic urothelial carcinoma."

Stock_Titan Posted - 03/19/24

$TYRA Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights https://www.stocktitan.net/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2023-financial-3736evb31ve4.html

insiderbuyingselling Posted - 6 months ago

$TYRA new insider selling: 200 shares. http://insiderbuyingselling.com/?t=TYRA

Stock_Titan Posted - 02/27/24

$TYRA Tyra Biosciences to Present at Upcoming Investor Conferences https://www.stocktitan.net/news/TYRA/tyra-biosciences-to-present-at-upcoming-investor-ymxalybdlpqb.html

insiderbuyingselling Posted - 7 months ago

$TYRA new insider selling: 1501 shares. http://insiderbuyingselling.com/?t=TYRA

StockScanners Posted - 7 months ago

$TYRA We reached 20 lets go!, testing resistance, lets see what this does into next week

insiderbuyingselling Posted - 7 months ago

$TYRA new insider selling: 9587 shares. http://insiderbuyingselling.com/?t=TYRA

ArcherGreenaway Posted - 7 months ago

$EVER $TYRA $SSP Analyst price target for today() https://live-alerts-stock-trades.daytrading.network

Stock_Titan Posted - 7 months ago

$TYRA Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference https://www.stocktitan.net/news/TYRA/tyra-biosciences-to-present-at-oppenheimer-s-34th-annual-healthcare-9ea44vd4hkyv.html

TickerDD_com Posted - 7 months ago

From 12/22/2023, looking back across 22 Month-Ends for TYRA, Percentage Change of Average Monthly Price had More Positives (64%) while Percentage Change of Average Monthly Volume had All Positives (100%) $TYRA #TYRA #TYRAStock #TickerDD #TYRAPrice https://www.youtube.com/watch?v=RYkrz2UwRRQ